

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/573 C12Q1/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, Sequence Search, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 00/04157 A (JANSSEN PHARMACEUTICA N.V; PANGALOS, MENLAS; NEEFS, JEAN-MARC, EDMOND,) 27 January 2000 (2000-01-27) cited in the application page 7, line 16 - page 10, line 11; claims 12-14,27-40; figures 4,12A,13C,14C</p> <p>-----</p> <p>-/-</p>	1-26

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 April 2005

Date of mailing of the international search report

07-07-2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Luis Alves, D

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PASSANI LUCIUS A ET AL: "N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases" MOLECULAR AND CHEMICAL NEUROPATHOLOGY, vol. 31, no. 2, 1997, pages 97-118, XP000987254 ISSN: 1044-7393 abstract page 107, last paragraph - page 108, paragraph 1 -----	1-26
A	ROSES ALLEN D ET AL: "Drug development and Alzheimer disease." THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY : OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR GERIATRIC PSYCHIATRY. 2003 MAR-APR, vol. 11, no. 2, March 2003 (2003-03), pages 123-130, XP002326526 ISSN: 1064-7481 the whole document -----	1-26
A	JACKSON P F ET AL: "DESIGN OF NAALADASE INHIBITORS: A NOVEL NEUROPROTECTIVE STRATEGY" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, 2001, pages 949-957, XP009033678 ISSN: 0929-8673 the whole document -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/011402

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-26 (all partially)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of Alzheimer's disease and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

2. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of liver cirrhosis and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

3. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of stomach tumour and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

4. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of uterus tumour and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

5. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of ovary tumour and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

6. claims: 1-26 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Methods of screening for therapeutical agents useful in the treatment of kidney tumour and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

7. claims: 1-26 (all partially)

Methods of screening for therapeutical agents useful in the treatment of prostate benign hyperplasia and methods of diagnosing said disease using as target N-acetylated alpha-linked acidic dipeptidase 2 (NAALADASE 2), as well as pharmaceutical compositions comprising NAALADASE 2 polynucleotide or polypeptide.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/011402

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0004157	A 27-01-2000	AU	772292 B2	22-04-2004
		AU	4920099 A	07-02-2000
		CA	2337362 A1	27-01-2000
		EP	1095148 A2	02-05-2001
		WO	0004157 A2	27-01-2000
		JP	2002520057 T	09-07-2002